VALN
Valneva·NASDAQ
--
--(--)
Market Open: --
--
--(--)
Pre-Market: --
Signals Analysis
Bullish signal 1
Bearish signal 3
Consensus Rating "Strong Buy"
Significant Net Income Decline
EPS Below Expectations
Revenue Below Expectations
Key Stats
0.0000DAY`S RANGE0.0000
0.000052 WK RANGE0.0000
0.0000
0.0000
--
--
--
--
--
--
--
--
--
--
--
--
--
--
0.0000
0.0000
0.0000
0.0000
About VALN
Valneva Se
An innovative biotech company that develops prophylactic vaccines for deadly and infectious diseases
Biological Technology
03/24/1999
05/06/2021
NASDAQ Stock Exchange
713
12-31
Depository Receipts (Ordinary Shares)
6 rue Alain Bombard, 44800 Saint-Herblain, France
--
Valneva SE was incorporated in France on March 24, 1999. The company is a specialty vaccine company focused on the development, manufacture and commercialization of preventive vaccines for infectious diseases. The company takes a highly specialized and targeted approach to vaccine research and development, focusing on vaccine solutions that address unmet needs to ensure that people's lives are transformed. The company uses a deep understanding of vaccine science, including expertise in multiple vaccine models, and established vaccine development capabilities to develop vaccines for diseases that are not yet preventable by vaccines or have limited effective treatment options. The company's current clinical portfolio consists of a number of highly differentiated vaccine candidates designed to provide preventive solutions for diseases with high unmet needs. VLA 1553 for chikungunya virus is the first and only chikungunya vaccine candidate to report positive Phase 3 top-line data and the first candidate to submit a biological product license application to the U.S. Food and Drug Administration.
Earnings Call
Q1/2025
Estimate EPS-0.2
Actual EPS-0.064776
Estimate Revenue45.49M
Actual Revenue53.15M
Contradictions Unveiled: IXCHIQ Vaccine Insights from 2025 Q1 Earnings Call
May 13,2025 04:46
Earnings Decrypt
Earnings Decrypt
Q2/2025
Estimate EPS-0.19
Actual EPS--
Estimate Revenue53.67M
Actual Revenue--
Valneva's Q2 2025: Unpacking Contradictions in IXCHIQ Sales, COVID-19 Manufacturing, and Trial Data Insights
Aug 12,2025 03:28
Earnings Decrypt
Earnings Decrypt
Company Financials
EPS
VALN has released its 2024 Q2 earnings. EPS was reported at -0.4, versus the expected -0.3, missing expectations. The chart below visualizes how VALN has performed over recent quarters, highlighting trends in earnings surprises.
Revenue & Expenses
VALN has released its 2025 Q3 earnings report, with revenue of 34.51M, reflecting a YoY change of -32.42%, and net profit of -52.05M, showing a YoY change of -405.66%. The Sankey diagram below clearly presents VALN's revenue sources and cost distribution.
Forecast
Wall Street Opinions
Price Target
Volume Profile
Trade Flow Insight
Seasonals
Community Forum
Loading...
Related News
No articles available
